In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...

Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

After pledging to allow politician and vaccine skeptic Robert Francis Kennedy Jr. | Trump's appointment follows his ...

Thursday’s appointment from President-elect Donald Trump made it official: noted vaccine skeptic Robert Francis Kennedy Jr.

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

A strand of Merz Pharmaceuticals’ star-studded promotion of the anti-wrinkle drug Xeomin has landed it a reprimand from the ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...